ChAd3-EBO-Z

BIOLOGICAL3 trials

Sponsors

University of Oxford, National Institute of Allergy and Infectious Diseases (NIAID), GlaxosSmithKline (GSK)

Conditions

Ebola EBOLAEbola DiseaseEbola Virus DiseaseImmunisation

Phase 1

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

CompletedNCT02495246

University of OxfordEbola Virus Disease

Start: 2015-09-21End: 2017-08-22Updated: 2018-04-11

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

CompletedNCT03583606

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Disease, Immunisation

Start: 2018-11-12End: 2020-01-14Updated: 2025-07-29

Unknown Phase

202091 (EBOLA Z CHAD3-005)

Active, not recruitingPACTR201504001092179

GlaxosSmithKline (GSK)Ebola EBOLA

Start: 2015-05-01Target: 3000Updated: 2026-01-27

Related Papers

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

2015-11-04162 citations